INFIQ (Infinity Pharmaceuticals) Cyclically Adjusted Book per Share: $1.62 (As of Jun. 2023)


INFIQ Infinity Pharmaceuticals Inc INFIQ
16 GF Score
Price $0.00
View Full Analysis

What is Infinity Pharmaceuticals Cyclically Adjusted Book per Share?

Infinity Pharmaceuticals INFIQ -99.00% 16 Cyclically Adjusted Book per Share is $1.62 as of Jun. 2023. GuruFocus rates INFIQ with a GF Score™ of 16/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Infinity Pharmaceuticals's adjusted book value per share for the three months ended in Jun. 2023 was $-0.412. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.62 for the trailing ten years ended in Jun. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-13), Infinity Pharmaceuticals's current stock price is $0.0001. Infinity Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 was $1.62. Infinity Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.00.


Infinity Pharmaceuticals  (OTCPK:INFIQ) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Infinity Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.0001/1.62
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Infinity Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Infinity Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Infinity Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Infinity Pharmaceuticals Cyclically Adjusted Book per Share Chart

Infinity Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.90 2.50 2.15 2.19 1.96

Infinity Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.32 2.18 1.96 1.79 1.62

INFIQ vs CLCS, RVLPQ, IVRN: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Infinity Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infinity Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infinity Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Infinity Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


INFIQ
16GF Score
Infinity Pharmaceuticals Inc INFIQ
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Infinity Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Infinity Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book= Book Value per Share /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.412/305.1090*305.1090
=-0.412

Current CPI (Jun. 2023) = 305.1090.

Infinity Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201309 4.788 234.149 6.239
201312 4.173 233.049 5.463
201403 3.567 236.293 4.606
201406 2.850 238.343 3.648
201409 5.039 238.031 6.459
201412 4.286 234.812 5.569
201503 2.470 236.119 3.192
201506 1.775 238.638 2.269
201509 2.716 237.945 3.483
201512 1.999 236.525 2.579
201603 1.249 238.132 1.600
201606 2.400 241.018 3.038
201609 2.059 241.428 2.602
201612 1.637 241.432 2.069
201703 1.463 243.801 1.831
201706 1.167 244.955 1.454
201709 1.053 246.819 1.302
201712 0.940 246.524 1.163
201803 0.845 249.554 1.033
201806 0.802 251.989 0.971
201809 1.051 252.439 1.270
201812 0.922 251.233 1.120
201903 0.692 254.202 0.831
201906 0.518 256.143 0.617
201909 0.326 256.759 0.387
201912 0.135 256.974 0.160
202003 -0.039 258.115 -0.046
202006 -0.198 257.797 -0.234
202009 -0.224 260.280 -0.263
202012 -0.357 260.474 -0.418
202103 0.587 264.877 0.676
202106 0.468 271.696 0.526
202109 0.361 274.310 0.402
202112 0.242 278.802 0.265
202203 0.112 287.504 0.119
202206 -0.012 296.311 -0.012
202209 -0.122 296.808 -0.125
202212 -0.213 296.797 -0.219
202303 -0.317 301.836 -0.320
202306 -0.412 305.109 -0.412

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $1.62 mean?
Infinity Pharmaceuticals (INFIQ) has a Cyclically Adjusted Book per Share of $1.62 as of Jun. 2023. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Infinity Pharmaceuticals and its competitors.
Is Infinity Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Infinity Pharmaceuticals' current Cyclically Adjusted Book per Share is $1.62. Overall, Infinity Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Infinity Pharmaceuticals' Cyclically Adjusted Book per Share compare to CLCS and RVLPQ?
Infinity Pharmaceuticals' Cyclically Adjusted Book per Share of $1.62 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Infinity Pharmaceuticals and its competitors. Infinity Pharmaceuticals's current Cyclically Adjusted Book per Share is $1.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infinity Pharmaceuticals stock overvalued right now?
Infinity Pharmaceuticals (INFIQ) has a current Cyclically Adjusted Book per Share of $1.62. The current Cyclically Adjusted Book per Share is $1.62. Infinity Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Infinity Pharmaceuticals (INFIQ), the current Cyclically Adjusted Book per Share is $1.62 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Infinity Pharmaceuticals Business Description

Address 1100 Massachusetts Avenue, Floor 4, Cambridge, MA, USA, 02138
Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company dedicated to developing novel medicines for people with cancer. It combines proven scientific expertise with a passion for developing novel small molecule drugs that target disease pathways for potential applications in oncology. It is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma.
16GF Score

Get the complete analysis for INFIQ

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price